|Mr. Paul V. Campanelli||Pres, CEO & Director||1.72M||N/A||1962|
|Mr. Blaise Coleman||Exec. VP & CFO||676.69k||N/A||1974|
|Mr. Terrance J. Coughlin||Exec. VP & COO||879.57k||N/A||1966|
|Mr. Matthew Joseph Maletta||Exec. VP & Chief Legal Officer||746.43k||N/A||1972|
|Mr. Antonio R. Pera||Pres of Par Pharmaceutical||N/A||N/A||1957|
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Endo International plc’s ISS Governance QualityScore as of August 1, 2018 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 8.